Dr. Feng Liu 刘峰
Chief Physician
Department of Head and Neck Radiation Oncology, Ward 1, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Biological intensity-modulated radiotherapy and stereotactic radiotherapy for head and neck tumors.
Dr. Liu holds degrees from Peking University Health Science Center and Peking Union Medical College. With 13 years of clinical experience, Dr. Liu was a visiting scholar at UC San Diego School of Medicine in 2016, studying precision radiotherapy and proton therapy. Dr. Liu leads projects on nasopharyngeal carcinoma treatment and has published six SCI papers.
Professional roles
- Member, Tumor Radiotherapy Professional Committee, Hunan Anti-Cancer Association
- Secretary, Youth Committee, Hunan Anti-Cancer Association
- Secretary, Nasopharyngeal Carcinoma Professional Committee, Hunan Anti-Cancer Association
- Deputy Director, Department of Tumor Radiotherapy Teaching and Research, Hunan Cancer Hospital
Name order: in Chinese the family name comes first (Liu Feng). Papers usually list the name as Feng Liu or Liu F.
Selected publications
40 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Drug Des Devel Ther, 2026 (senior author): Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in Patients with Platinum-Resistant or Immunotherapy-Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective, Real-World Study. PubMed 42415935
- NPJ Precis Oncol, 2026 (first author): LINC00839 transcriptionally activated by ELK1 represses ferroptosis in nasopharyngeal carcinoma by regulating UPF1/RCHY1/DJ-1 axis. PubMed 42135459
- BMC Cancer, 2025 (senior author): DWI-guided DP-IMRT and conventional MRI-based IMRT in head and neck squamous cell carcinoma: a comparative study. PubMed 40849450
- Int J Radiat Oncol Biol Phys, 2025 (senior author): In Reply to Kite et al. PubMed 40240112
- Int J Radiat Oncol Biol Phys, 2025 (senior author): Toxicity and Efficacy of Different Target Volume Delineations of Radiation Therapy Based on the Updated Radiation Therapy Oncology Group/National Research Group and European Organization for Research and Treatment of Cancer Guidelines in Patients With Grade 3-4 Glioma: A Randomized Controlled Clinical Trial. PubMed 39615657
- Cell Death Dis, 2024 (first author): Cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2. PubMed 38637504
- BMJ Support Palliat Care, 2024 (first author): Desire for hastened death in advanced cancer: cross-sectional study in China. PubMed 36357163
- BMJ Support Palliat Care, 2024 (senior author): Lung cancer distress: screening thermometer meta-analysis. PubMed 35172980
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion